Reumatologia最新文献

{"title":"Endocrine dysfunctions as complications and comorbidities of juvenile idiopathic arthritis.","authors":"Monika Kamińska, Aleksandra Spyra, Michael Schröter, Aleksandra Sierpińska, Katarzyna Moczyróg, Izabela Rosół","doi":"10.5114/reum/204738","DOIUrl":"10.5114/reum/204738","url":null,"abstract":"<p><p>Juvenile idiopathic arthritis (JIA) is the most prevalent chronic rheumatic disease in children, primarily affecting the joints but also influencing various organ systems, including the endocrine system. The interplay between JIA and endocrine dysfunctions remains an area of growing interest, as autoimmune and inflammatory mechanisms may contribute to the development of comorbid conditions. This review explores genetic markers associated with both JIA and endocrine disorders, the role of immune system dysregulation, and the impact of disease-modifying therapies on hormonal function. Additionally, the effects of chronic inflammation on endocrine homeostasis and metabolic regulation are discussed. Particular attention is given to conditions such as type 1 diabetes, Hashimoto's thyroiditis, and Cushing's syndrome, which may either precede JIA, arise as complications, or be exacerbated by its treatment. Effective JIA management requires an understanding of these mechanisms and a multidisciplinary approach.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 5","pages":"348-357"},"PeriodicalIF":1.7,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic syndrome in postmenopausal women with osteoporosis and its relationship with bone density and turnover markers.","authors":"Bahouq Hanane, Bahouq Madiha, Soulaymani Abdelmajid","doi":"10.5114/reum/203545","DOIUrl":"10.5114/reum/203545","url":null,"abstract":"<p><strong>Introduction: </strong>Previous research has explored the uncertain association between metabolic syndrome (MetS) and bone mineral density (BMD). The objective of this study was to determine the prevalence of MetS in postmenopausal Moroccan women with osteoporosis and to examine the relationship between MetS, BMD, and bone turnover markers among this sample.</p><p><strong>Material and methods: </strong>This was a cross-sectional study of 100 postmenopausal women. Anthropometric parameters and biochemical blood tests were assessed. Bone mineral density and <i>T</i>-scores in the lumbar spine and femoral neck were screened. Bone mineral density was determined using dual-energy X-ray absorptiometry. National Cholesterol Education Program-Adult Treatment Panel III criteria were used to define MetS. The association between the MetS components, BMD, and bone turnover markers was evaluated by partial correlation and multiple linear regression analysis using SPSS software.</p><p><strong>Results: </strong>Prevalence of MetS in our patients was 44%. The mean age of patients with and those without MetS was 63.82 ±8.65 and 60.39 ±7.93, respectively; <i>p</i> = 0.04. Lumbar spine BMD correlated significantly with high-density lipoprotein cholesterol (HDL-C; <i>r</i> = -0.233; <i>p</i> = 0.02). Lumbar spine <i>T</i>-score correlated with systolic blood pressure (SBP; <i>r</i> = -0.196; p = 0.005) and waist circumference (<i>r</i> = 0.274; <i>p</i> = 0.006). Femoral neck <i>T</i>-score correlated with diastolic blood pressure (<i>r</i> = -0.218; <i>p</i> = 0.02) and waist circumference (<i>r</i> = 0.294; <i>p</i> = 0.003). Osteocalcin inversely correlated with HDL-C and fasting plasma glucose (<i>r</i> = -0.199; <i>p</i> = 0.04 and <i>r</i> = -0.238; <i>p</i> = 0.01 respectively). Carboxy-terminal cross-linked telopeptide of type I collagen correlated negatively with HDL-C and SBP (<i>r</i> = -0.238; <i>p</i> = 0.02 and <i>r</i> = -0.243; <i>p</i> = 0.01 respectively). After linear regression, lumbar spine BMD was associated with age (β = -2.120, <i>p</i> = 0.04), SBP (β = -0.112, <i>p</i> = 0.01) and waist circumference (β = 0.253, <i>p</i> = 0.001). Femoral neck BMD was associated with age (β = -0.227, <i>p</i> = 0.02) and waist circumference (β = 0.258, <i>p</i> = 0.008).</p><p><strong>Conclusions: </strong>The prevalence of MetS was associated with osteoporosis in postmenopausal Moroccan women, predominantly driven by age, blood pressure, and central obesity.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 5","pages":"321-330"},"PeriodicalIF":1.7,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673481/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of anti-interleukin-6 treatment in familial Mediterranean fever: a systematic literature review.","authors":"Olfa Saidane, Selma Bouden, Ameni Jerbi, Leila Rouached, Ines Mahmoud, Rawdha Tekaya, Aicha Ben Tekaya, Leila Abdelmoula","doi":"10.5114/reum/199741","DOIUrl":"10.5114/reum/199741","url":null,"abstract":"<p><strong>Introduction: </strong>Biological treatments are indicated in familial Mediterranean fever (FMF) patients with colchicine resistance or intolerance. Interleukin-1 (IL-1) inhibitors may not yield sufficient efficacy and safety. Interleukin-6 inhibitors (tocilizumab - TCZ) have been suggested to be potentially beneficial. This systematic literature review aimed to evaluate the existing data on the efficacy and safety of IL-6 inhibitors in the treatment of FMF.</p><p><strong>Material and methods: </strong>A systematic literature review was conducted using PubMed, Embase, Scopus, Web of Science, and the Cochrane Library to identify literature published until February 2024 on \"Tocilizumab\" OR \"Interleukin-6 inhibitor\" AND \"Familial Mediterranean Fever\". This study was conducted according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines.</p><p><strong>Results: </strong>A total of 11 studies were included, corresponding to 68 patients: 6 studies were case reports, 3 were case series, and 2 were randomized control trials. Tocilizumab was indicated mainly for amyloid A (AA) amyloidosis and resistance/intolerance to other drugs. Tocilizumab showed efficacy in controlling FMF attacks and disease symptoms including fever, abdominal pain, arthritis and arthralgia. Inflammatory markers including C-reactive protein and serum amyloid A protein decreased. A decrease in proteinuria levels was reported in 20 patients. Adverse events were recorded in one-third of patients and led to TCZ discontinuation in 5 patients. No deaths associated with anti-IL-6 treatment were documented within a median follow-up period of 13 months.</p><p><strong>Conclusions: </strong>Although the duration of follow-up of TCZ was short, we concluded that TCZ might present an acceptable profile regarding efficacy and safety in adult FMF patients. Our data suggest that TCZ could be a good treatment option after IL-1 inhibitors and warrants further investigation.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 5","pages":"337-347"},"PeriodicalIF":1.7,"publicationDate":"2025-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12673480/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145678516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum levels of tumor necrosis factor-like cytokine 1A and its receptors, death receptor 3 and decoy receptor 3, in patients with spondyloarthropathies: preliminary results from a cross-sectional study.","authors":"Emilia Anna Frąckiel, Adrianna Błahuszewska-Omyła, Paweł Bielecki, Magdalena Bagrowska, Natalia Szymańska, Krzysztof Kowal, Otylia Kowal-Bielecka","doi":"10.5114/reum/203129","DOIUrl":"10.5114/reum/203129","url":null,"abstract":"<p><strong>Introduction: </strong>Tumor necrosis factor (TNF)-like cytokine 1A (TL1A) is a member of the TNF superfamily of cytokines, involved in regulation of the immune and inflammatory response. Recently, therapies aimed at blockade of the TL1A pathway have shown benefit in the treatment of inflammatory bowel diseases (IBDs). However, very little is known regarding activation of the TL1A axis in spondyloarthropathies (SpA), which are clinically and pathogenetically linked to IBDs. Our study investigated soluble forms of TL1A and its receptors, death receptor 3 (DR3) and decoy receptor 3 (DcR3), in the serum of patients with SpA, and evaluated potential associations between concentrations of the investigated molecules and clinical features of SpA.</p><p><strong>Material and methods: </strong>Tumor necrosis factor-like cytokine 1A, DR3, and DcR3 concentrations were measured (using enzyme linked immunosorbent assay - ELISA) in the serum of 82 patients with SpA and 36 healthy controls.</p><p><strong>Results: </strong>We found no significant difference in serum concentrations of TL1A or DR3 between the study and the control groups. However, we observed a significantly higher concentration of DcR3 (median [min.-max.]: 292.31 [93.241-13,862.10] pg/ml) in patients with SpA than in the controls (median [min.-max.]: 126.73 [10.68-1,482.74] pg/ml; <i>p</i> = 0.003). The DR/DcR ratio was significantly lower in patients with SpA (median [min.-max.]: 4.05 [0.14-235.39]) than in the controls (17.22 [0.00-750.66]; <i>p</i> = 0.002). Moreover, there were weak but significant correlations between serum concentrations of DcR and TL1A (Spearman's rho: 0.28, <i>p</i> < 0.05) and between DcR3 and C-reactive protein as well as erythrocyte sedimentation rate values (Spearman's rho: 0.25 and 0.24 respectively, <i>p</i> < 0.05 for both) in patients with SpA.</p><p><strong>Conclusions: </strong>The results of our study indicate that the TL1A/DR3/DcR3 axis is activated in patients with SpA and may represent a new target for therapies in this group of diseases. Further studies are needed to confirm our data.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"216-221"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503155/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Modern diagnostics for dry eye disease: implications for rheumatology.","authors":"Adam Wylęgała","doi":"10.5114/reum/209449","DOIUrl":"10.5114/reum/209449","url":null,"abstract":"","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"213-215"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503148/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Physiotherapy management strategies for chronic pain control in patients with lumbosacral transitional vertebrae and low back pain: a review of the literature.","authors":"Justyna Frasuńska, Barbara Stypińska, Beata Tarnacka","doi":"10.5114/reum/202295","DOIUrl":"10.5114/reum/202295","url":null,"abstract":"<p><p>Physiotherapy is a widely used form of treatment of low back pain (LBP) and is important in non-surgical/surgical management of patients with lumbosacral transitional vertebrae (LSTV). This review presents physiotherapeutic management in LSTV patients with LBP. A search was performed in PubMed, Scopus, Embase, Medline, and Google Scholar between November 20 and December 31, 2023. The mean age of patients was 39 years. The patients had an average of 13 sessions, and the average duration of physiotherapy was 3 weeks (frequency of 1-5 sessions/week). The physiotherapy methods used were: manual therapy, mobility training, motor control training, myofascial approach and hot packs, and electrotherapy. Outcome measures were pain scales, range of motion testing, improvement in sleep, return to work, physical activity, or muscle thickness. The reviewed papers described pain reduction, though pain recurrence occurred with varying frequency (1-3 months after therapy). Physiotherapy for LSTV patients should be a first-line treatment, but requires an individualized approach.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"251-265"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-interferon α-antibodies in pediatric patients with COVID-19 and long COVID.","authors":"Oksana Boyarchuk, Vita Perestiuk, Tetiana Kosovska, Liubov Volianska","doi":"10.5114/reum/204365","DOIUrl":"10.5114/reum/204365","url":null,"abstract":"<p><strong>Introduction: </strong>The involvement of neutralizing antibodies against type I interferon (IFN-I) in the development of severe coronavirus disease 2019 (COVID-19) in adult patients has been well documented. However, the role of anti-IFN-α autoantibodies, especially non-neutralizing types, remains underexplored, especially in children. Our study aimed to determine the frequency of antibodies against IFN-α in children with COVID-19 and long COVID, as well as their potential role in the development of long COVID.</p><p><strong>Material and methods: </strong>The study included 78 children aged 1 to 17 years with a documented history of COVID-19 from September 2022 to August 2023. All patients were divided into three groups: hospitalized with COVID-19, hospitalized with long COVID symptoms, and monitored in an outpatient care department for mild COVID-19 or symptoms of long COVID. Human anti-IFN-α antibodies were detected using enzyme-linked immunosorbent assay.</p><p><strong>Results: </strong>Binding anti-IFN-α antibodies were detected in 2/78 (2.6%) children with COVID-19 of varying severity. One patient with anti-IFN-α antibodies had comorbidities (obesity, allergic rhinitis) and critical COVID-19 pneumonia (SpO₂ - 80%), significant inflammatory changes (neutrophil-to-lymphocyte ratio: 18.8, C-reactive protein: 95.5 mg/l), and a high D-dimer level, and later developed long COVID symptoms. In the second case, COVID-19 in a 13-year-old girl without significant comorbidities was not severe, but leukopenia and lymphopenia were observed. Subsequently, she developed pronounced long COVID symptoms (fatigue, reduced appetite, insomnia, headache, decreased attention, difficulty concentrating, weight loss, tachycardia, dizziness), which persisted for up to 6 months after the acute infection. The detection rate of binding anti-IFN-α antibodies among hospitalized COVID-19 patients was 4%, compared to 25% among patients with severe/critical disease. Among children who developed long COVID symptoms, anti-IFN-α was found in 3.4%.</p><p><strong>Conclusions: </strong>Further studies in larger cohorts are needed to assess the role of anti-IFN-α antibodies (both neutralizing and non-neutralizing) in the development of long COVID symptoms, to understand their clinical significance, and to examine their dynamics over time.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"229-235"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503149/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What are the characteristics of paradoxical effects in the Biotherapies Registry of the Moroccan Society of Rheumatology?","authors":"Laila Taoubane, Abdellah El Maghraoui, Redouane Niamane, Ihsane Hmamouchi, Fadoua Allali, Rachid Bahiri, Ouafae Mkinsi, Hasna Hassikou, Imad Ghozlani, Bezza Ahmed","doi":"10.5114/reum/205366","DOIUrl":"10.5114/reum/205366","url":null,"abstract":"<p><strong>Introduction: </strong>The main objective of our study was to assess the prevalence of paradoxical reactions in patients with chronic inflammatory rheumatism treated with biologic drugs, while secondary objectives were to determine the type of paradoxical reactions and to investigate associated factors.</p><p><strong>Material and methods: </strong>We conducted a descriptive cohort study using 36-month frozen data from the RBSMR registry. This is a registry promoted by the Moroccan Society of Rheumatology, including patients treated for rheumatoid arthritis (RA) or spondyloarthritis treated with a biologic drug. The paradoxical reaction was defined by the appearance of a pathology that could be treated by biological drugs. We investigated the prevalence of paradoxical reactions, and the factors associated with their occurrence. Statistical analysis was performed using JAMOVI software.</p><p><strong>Results: </strong>We analyzed 440 patients in the RBSMR. Paradoxical reactions were found in 19 patients (4.6%). The mean time to onset of paradoxical manifestations was 30 weeks (1-144 weeks). Uveitis was the most frequent paradoxical reaction, found in 9 patients, followed by psoriasis in 7 patients, and then pyoderma gangrenosum, lichen, and granulomatous dermatitis in only 1 patient each. These paradoxical effects were found predominantly in men (57.9% of cases). Etanercept was the most prescribed biologic, in 52.6% of patients with paradoxical reactions, followed by adalimumab in 21.1%, golimumab in 15.8%, and secukinumab in 5.3%. Permanent discontinuation of biological treatment was recommended for all patients. In univariate analysis, the occurrence of a paradoxical effect was related to sex (<i>p</i> = 0.05) and to disease activity in patients with RA (<i>p</i> = 0.04).</p><p><strong>Conclusions: </strong>Our study suggests that there is a low prevalence of paradoxical effects in our population. However, these are reactions that need to be identified and investigated to improve the management of our patients with chronic inflammatory rheumatism.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"244-250"},"PeriodicalIF":1.7,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503150/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing cardiovascular risk in rheumatoid arthritis patients on Janus kinase inhibitors: real-world data from the European Alliance of Associations for Rheumatology-adapted CUORE risk algorithm.","authors":"Marco Tasso, Luisa Costa, Nicoletta Bertolini, Antonio Del Puente, Rosario Peluso, Alfonso Oriente, Francesca Foglia, Mario Cascone, Francesco Caso","doi":"10.5114/reum/207507","DOIUrl":"10.5114/reum/207507","url":null,"abstract":"<p><p>Janus kinase inhibitors (JAKi) are effective treatments for rheumatoid arthritis (RA), but growing evidence raises cardiovascular (CV) safety concerns. Given the elevated baseline CV risk in RA, appropriate risk stratification is essential. We retrospectively analyzed 116 RA patients treated with JAKi at the University of Naples Federico II (2020-2025), excluding those with previous CV events. Cardiovascular risk was assessed using the CUORE algorithm, adjusted with the European Alliance of Associations for Rheumatology-recommended 1.5 multiplication factor. Patients were stratified into low (37.9%), intermediate (48.3%), and high (13.8%) risk categories. Over a median follow-up of 25.6 months, only one major CV event (myocardial infarction) was recorded, with no CV deaths. Despite the algorithm being developed for the general population, it appears feasible for RA patients on JAKi. Our findings suggest its potential role in guiding CV prevention strategies, although larger, multicenter studies are needed to confirm its predictive value and integrate RA-specific variables.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"281-283"},"PeriodicalIF":1.7,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503153/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translation and validation of Polish versions of the Psoriasis Epidemiology Screening Tool and the Early Arthritis for Psoriatic Patients questionnaire.","authors":"Kinga Maria Tyczyńska, Piotr Krzysztof Krajewski, Daria Kuc, Piotr Krawiec, Piotr Wawryka, Adam Zalewski, Brygida Kwiatkowska, Jacek Cezary Szepietowski, Bogdan Piotr Batko","doi":"10.5114/reum/209210","DOIUrl":"10.5114/reum/209210","url":null,"abstract":"<p><strong>Introduction: </strong>Early detection of psoriatic arthritis (PsA) is critical to prevent joint damage and disability. The Psoriasis Epidemiology Screening Tool (PEST) and the Early Arthritis for Psoriatic Patients (EARP) questionnaire are established instruments for identifying PsA in patients with psoriasis. However, validated Polish versions were not available. This study aimed to translate and validate the Polish versions of both questionnaires.</p><p><strong>Material and methods: </strong>The translation process followed international guidelines. Two independent forward translations from English to Polish were performed by translators (P.K.K., K.M.T.), and a unified version was established by a third consultant (J.C.S.). This was followed by two independent back translations from Polish into English (A.Z., P.W.) to ensure accuracy. The back translations were presented to the authors of the original questionnaires. Cognitive debriefing was conducted with eight patients diagnosed with PsA to enhance clarity and cultural relevance. The final Polish questionnaires were then administered to 45 adult patients diagnosed with PsA, as defined by the Classification Criteria for Psoriatic Arthritis, who were recruited from three clinical centers. Participants completed the questionnaires twice within a 3-to-5-day interval. The obtained data were subjected to statistical analysis.</p><p><strong>Results: </strong>The Polish versions of PEST and EARP demonstrated adequate internal consistency, with Cronbach's α values of 0.712 for PEST and 0.771 for EARP. Test-retest reliability was robust, with intraclass correlation coefficient values of 0.731 and 0.730 for the respective questionnaires. No statistically significant differences were observed between the two assessments (<i>p</i> > 0.05). A limitation of this study is the absence of convergent validity, primarily due to the lack of other validated Polish screening instruments.</p><p><strong>Conclusions: </strong>The validated Polish versions of the PEST and the EARP questionnaires are reliable instruments for screening PsA. Their implementation in clinical practice may facilitate early diagnosis and referral to rheumatology, thereby enhancing patient management in Poland.</p>","PeriodicalId":21312,"journal":{"name":"Reumatologia","volume":"63 4","pages":"236-243"},"PeriodicalIF":1.7,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12503157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145252244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}